PPCB (Propanc Biopharma) 6-1 Month Momentum %: -75.52% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PPCB Propanc Biopharma Inc PPCB
29 GF Score
Price $1.64
! 2 Warning Signs
View Full Analysis

What is Propanc Biopharma 6-1 Month Momentum %?

Propanc Biopharma PPCB +0.61% 29 6-1 Month Momentum % is -75.52% as of Jul. 16, 2026. GuruFocus rates PPCB with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,383 Biotechnology companies, Propanc Biopharma ranks worse than 96.17% on this metric.

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-07-16), Propanc Biopharma's 6-1 Month Momentum % is -75.52%.

The industry rank for Propanc Biopharma's 6-1 Month Momentum % or its related term are showing as below:

PPCB's 6-1 Month Momentum % is ranked worse than
96.17% of 1383 companies
in the Biotechnology industry
Industry Median: -16.36 vs PPCB: -75.52

Propanc Biopharma  (NAS:PPCB) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Propanc Biopharma 6-1 Month Momentum % Related Terms

PPCB vs GRI, BGMS, SPRC: 6-1 Month Momentum % Comparison

For the Biotechnology subindustry, Propanc Biopharma's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Propanc Biopharma 6-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's 6-1 Month Momentum % falls into.


PPCB
29GF Score
Propanc Biopharma Inc PPCB
6-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Propanc Biopharma  (NAS:PPCB) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-1 Month Momentum % →
What does a 6-1 Month Momentum % of -75.52% mean?
Propanc Biopharma (PPCB) has a 6-1 Month Momentum % of -75.52% as of Jul. 16, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Propanc Biopharma and its competitors. According to the industry distribution chart, Propanc Biopharma ranks #1330 out of 1383 companies in the Biotechnology industry, placing it in the top 96.2%.
Is Propanc Biopharma's 6-1 Month Momentum % too high?
Propanc Biopharma's current 6-1 Month Momentum % is -75.52%. Based on the distribution chart, Propanc Biopharma ranks #1330 out of 1383 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Propanc Biopharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Propanc Biopharma's 6-1 Month Momentum % compare to GRI and BGMS?
According to the Biotechnology industry distribution chart, Propanc Biopharma ranks #1330 out of 1383 companies for 6-1 Month Momentum %. This places Propanc Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Propanc Biopharma and its competitors. Propanc Biopharma's current 6-1 Month Momentum % is -75.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Propanc Biopharma stock overvalued right now?
Propanc Biopharma (PPCB) has a current 6-1 Month Momentum % of -75.52%. The current 6-1 Month Momentum % is -75.52%. Propanc Biopharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Propanc Biopharma (PPCB), the current 6-1 Month Momentum % is -75.52% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Propanc Biopharma Business Description

Address 302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score

Get the complete analysis for PPCB

6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.64
Price